Seminal vesicles

Direct Biologics Announces Publication of Significant Survival Benefit with ExoFlo™ in its Phase 2 Randomized Controlled Clinical Trial in the Journal CHEST

Retrieved on: 
Wednesday, July 12, 2023
Other Health, Research, General Health, Pharmaceutical, Infectious Diseases, Clinical Trials, Science, COVID-19, Biotechnology, Stem Cells, Other Science, Health, Therapy, Overalls, Clinical trial, Trial of the century, Regenerative medicine, EVS, Incidence, Respiratory failure, Seminal vesicles, Patient, Risk, Acute respiratory distress syndrome, Mortality, VFD, Ageing, FDA, Death, Treatment, Safety, Pharmaceutical industry

“A critical finding of this study was the safety profile of ExoFlo.

Key Points: 
  • “A critical finding of this study was the safety profile of ExoFlo.
  • There was a lack of adverse or serious adverse events in this very sick patient population.
  • Over the duration of the clinical trial, no treatment-related adverse events were reported.
  • In addition, a trend in dose response was observed for VFDs in both moderate and severe ARDS in this age group.

Atossa Therapeutics Announces Sponsored Research Agreement with Weill Cornell Medicine to Address Treatment Challenges in Triple Negative Breast Cancer

Retrieved on: 
Thursday, July 6, 2023
Triple-negative breast cancer, TNBC, ER, Breast, Cancer, Woman, Research, Atossa, Annals of Pediatric Cardiology, SERM, Seminal vesicles, Patient, Risk, Cardiology, Weill Cornell Medicine, Neoplasm, Progesterone, Therapy, Recurrence, Estrogen receptor, Phenotype, Metastasis, Breast cancer, Medical imaging, Birth control

SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces a strategic, sponsored research agreement with Weill Cornell Medicine to study the potential of inducing estrogen receptor (ER) expression in triple-negative breast cancer (TNBC).

Key Points: 
  • SEATTLE, July 06, 2023 (GLOBE NEWSWIRE) -- Atossa Therapeutics, Inc. (Nasdaq: ATOS), a clinical stage biopharmaceutical company developing innovative proprietary medicines to address significant unmet needs in oncology with a focus on breast cancer, today announces a strategic, sponsored research agreement with Weill Cornell Medicine to study the potential of inducing estrogen receptor (ER) expression in triple-negative breast cancer (TNBC).
  • “We look forward to working with Atossa and think this project could provide proof of principle for novel approaches to estrogen receptor reinduction in triple negative breast cancer,” said Dr. Lyden.
  • “It’s called triple-negative breast cancer because it does not have any of the receptors that are commonly found in most breast cancers.
  • Activating the estrogen receptor and converting the tumor to ER+ would fundamentally transform the treatment paradigm for these patients.”

Global Liquid Biopsy Market Report 2023: Increasing Preference for Non-invasive Procedures Drives Growth - ResearchAndMarkets.com

Retrieved on: 
Monday, June 19, 2023
Health, Oncology, Q.9, DNA, Circulating tumor DNA, Nucleic acid thermodynamics, NGS, Liquid biopsy, Cancer, Biomarker, Chinese, EVS, Incidence, Seminal vesicles, Hospital, Laboratory, Growth, Neoplasm, Metastasis, Medical imaging, Typesetting, Mineral wool

What are the drivers and challenges of the global liquid biopsy market?

Key Points: 
  • What are the drivers and challenges of the global liquid biopsy market?
  • Q.5 What are the business risks and threats to the global liquid biopsy market?
  • Q.6 What are the emerging trends in this liquid biopsy market and the reasons behind them?
  • Q.11 What M&A activities did take place in the last five years in the global liquid biopsy market?

Global Exosome Market Research Report 2023-2030: Market Size, Forecasts, Trials, and Trends with Company Profiles of 118 Competitors - ResearchAndMarkets.com

Retrieved on: 
Friday, June 9, 2023
Health, Biotechnology, Karolinska Institute, Fresenius Medical Care, Partnership, Therapy, Urine, Takeda, Serum, Breast milk, Tears, Exosome, Liquid biopsy, Cancer, Lead, Immunity, MicroRNA, Research, Cell, Lung cancer, Biomarker, Inflammation, Regenerative medicine, Plasma, Seminal vesicles, Acquisition, MSC, Publication, DSM-IV codes, Patient, Medicine, CSF, Diagnosis, FDA, Fluid mechanics, Disease, Metastasis, Saliva, Prostate cancer, Medical device, Medical imaging, Pharmaceutical industry

The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2023" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "The Global Exosome Market - Market Size, Forecast, Trials, and Trends, 2023" report has been added to ResearchAndMarkets.com's offering.
  • To characterize the rapidly expanding exosome market, the analyst has released a 312-page global market report that explores the growing demand for exosome therapeutics, diagnostics, research tools, and manufacturing technologies.
  • The report reveals trend rate data for exosome patents, grants, scientific publications, and clinical trials.
  • It features company profiles for 118 global competitors from across the exosome marketplace.

Europe Circulating Biomarkers and Extracellular Vesicles Annual Conference 2023 (Rotterdam, Netherlands - June 19-20, 2023) - ResearchAndMarkets.com

Retrieved on: 
Wednesday, May 24, 2023
Health, Biometrics, DNA, Therapy, Nucleic acid thermodynamics, Offerings, Research, Biomarker, Exosome, Chinese, EVS, Seminal vesicles, Conference, Retail, Video game

The "5th Annual Circulating Biomarkers and Extracellular Vesicles Europe 2023" conference has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "5th Annual Circulating Biomarkers and Extracellular Vesicles Europe 2023" conference has been added to ResearchAndMarkets.com's offering.
  • The Circulating Biomarkers & Extracellular Vesicles Europe 2023 Conference to be held at the Hilton Rotterdam, The Netherlands.
  • This annual conference brings together academics and industry participants from around the world focused on research, biomarker analyses, and therapeutics development leveraging the cargo from various classes of circulating biomarkers including cfDNA, CTCs as well as Exosomes and Extracellular Vesicles (EVs).
  • The nexus of the various conference tracks that together constitute this conference enables scientific exchange, crossovers across fields, as well as networking across disciplines.

Europe Circulating Biomarkers and Extracellular Vesicles Annual Conference 2023 (Rotterdam, Netherlands - June 19-20, 2023)

Retrieved on: 
Friday, May 26, 2023
DNA, Therapy, Nucleic acid thermodynamics, Offerings, Research, Biomarker, Exosome, Chinese, EVS, Seminal vesicles, Conference, Retail, Video game

An important component of this conference is the emphasis on companies and technology innovation driven by the commercial sector -- these are represented via exhibits and technology spotlight presentations throughout the programme of the conference.

Key Points: 
  • DUBLIN, May 26, 2023 /PRNewswire/ -- The "5th Annual Circulating Biomarkers and Extracellular Vesicles Europe 2023" conference has been added to ResearchAndMarkets.com's offering.
  • The Circulating Biomarkers & Extracellular Vesicles Europe 2023 Conference to be held at the Hilton Rotterdam, The Netherlands.
  • This annual conference brings together academics and industry participants from around the world focused on research, biomarker analyses, and therapeutics development leveraging the cargo from various classes of circulating biomarkers including cfDNA, CTCs as well as Exosomes and Extracellular Vesicles (EVs).
  • The nexus of the various conference tracks that together constitute this conference enables scientific exchange, crossovers across fields, as well as networking across disciplines.

ExoCoBio obtained a US Patent for Rose Stem Cell-derived Exosome (RSCE™)

Retrieved on: 
Friday, May 19, 2023
Survival rate, Patent, Human, Exosome, United States patent law, IL-6, Research, MicroRNA, Applied aesthetics, Protein, Seminal vesicles, Personal Care Products Council, Collagen, Congress, INCI, Wound healing, Pharmaceutical industry

SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- ExoCoBio, one of the top three exosome companies in the world, announced that it has obtained a patent (US Application No: 17/141,693) from the US Patent and Trademark Office for a cosmetic composition containing rose stem cell-derived exosomes or extracellular vesicles.

Key Points: 
  • SEOUL, South Korea, May 19, 2023 /PRNewswire/ -- ExoCoBio, one of the top three exosome companies in the world, announced that it has obtained a patent (US Application No: 17/141,693) from the US Patent and Trademark Office for a cosmetic composition containing rose stem cell-derived exosomes or extracellular vesicles.
  • In this patent, ExoCoBio used its proprietary technology ExoSCRT™ process to mass-culture stem cells derived from roses and isolate high-purity exosomes (RSCE™) from the culture medium.
  • Various efficacy evaluations were performed on the mass-produced RSCE™, resulting in a significant increase in collagen production from human skin fibroblasts.
  • In particular, with the most data and patents, ExoCoBio has been at the forefront of plant stem cell-derived exosome research worldwide.

STRM.BIO Appoints Independent Director Dawn Bell, PharmD, to its Board

Retrieved on: 
Wednesday, May 17, 2023
Emory University, Bell, Medical Affairs Bureau, Doctor of Pharmacy, University, Therapy, Hematology, Editas Medicine, EVS, Senior, Seminal vesicles, GM, Growth, FDA, VC, BD, Pharmaceutical industry, Sacubitril/valsartan, Novartis

Most recently, she was at Novartis where she held leadership roles in global drug development, medical affairs, and portfolio strategy.

Key Points: 
  • Most recently, she was at Novartis where she held leadership roles in global drug development, medical affairs, and portfolio strategy.
  • "We are excited to welcome Dawn to our Board, as she brings exceptional strategic and operational experience and leadership to our organization," said Jonathan Thon, Ph.D., CEO and Founder of STRM.BIO.
  • "Dawn has an impressive track record of creating value in the biopharmaceutical industry and fostering the growth of companies.
  • "I look forward to joining the STRM.BIO Board and working with the leadership team and other Board members at this pivotal time for the company."

Mursla Bio Unlocks New Biomarker Discovery Approach in Liquid Biopsy and Precision Medicine

Retrieved on: 
Tuesday, May 16, 2023
Professional Services, Health, Medical Devices, Health Technology, Finance, Pharmaceutical, Biotechnology, Tissue, Red, EV, WHO model list of essential in vitro diagnostics, Workflow, Hepatocellular carcinoma, Bio, Liquid biopsy, Cancer, Extracellular vesicle, Biomarker, Doctor of Philosophy, Lung, Trial of the century, EVS, Liver cancer, Plasma, Seminal vesicles, ISEV, Patient, Blood, Medicine, Kidney, Liver, International Society for Extracellular Vesicles, Poster, HCC, International Society, Conditional sentence, Disease, Medical imaging, Vaccine, Fireworks

Mursla Bio will present its novel tissue-specific Extracellular Vesicle (EV) isolation technology, NEXPLOR, at the International Society for Extracellular Vesicles (ISEV) annual meeting, paving the way for a new approach to biomarker discovery in liquid biopsy and precision medicine.

Key Points: 
  • Mursla Bio will present its novel tissue-specific Extracellular Vesicle (EV) isolation technology, NEXPLOR, at the International Society for Extracellular Vesicles (ISEV) annual meeting, paving the way for a new approach to biomarker discovery in liquid biopsy and precision medicine.
  • Conventional isolation techniques cannot distinguish between EVs based on their origin, thus limiting progress in disease biomarker discovery.
  • Dr Tomás Dias (PhD), CTO, Mursla Bio commented: “NEXPLOR can isolate specific sub-populations of EVs, such as liver-specific EVs, from complex fluids like blood.
  • This is an important step forward to develop EV-based liquid biopsy and precision medicine applications.”
    NEXPLOR is part of Mursla Bio’s ExoPheno™ platform and has been engineered to improve the translation of EV-based diagnostics into clinics.

Evox Therapeutics Presents Progress Across its DeliverEX® Platform Highlighting Advances in Exosome-Mediated Delivery of Genetic Medicines Including Gene Editing and RNA Therapeutics

Retrieved on: 
Friday, May 12, 2023
Tissue, Single, Central nervous system, EV, Gene, Intrinsic termination, Exosome, Onto Innovation, Cell, RNA, Quantification, CNS, Messenger, Small RNA, Seminal vesicles, Flow cytometry, Animal, ISEV, Buffer, Annual general meeting, American Society of Gene and Cell Therapy, RNA interference, International Society for Extracellular Vesicles, LNP, Therapy, Society, International Society, Vaccine

The six oral presentations and posters highlight the progress made in leveraging the versatility of the Company’s DeliverEX® exosome platform to deliver a wide range of genetic medicines ranging from genome editors, RNAi and mRNA as well as presenting on other exosome-related advances.

Key Points: 
  • The six oral presentations and posters highlight the progress made in leveraging the versatility of the Company’s DeliverEX® exosome platform to deliver a wide range of genetic medicines ranging from genome editors, RNAi and mRNA as well as presenting on other exosome-related advances.
  • Exosome delivery to the CNS (oral presentation): Gupta et al., provide an overview of the ability to engineer exosomes to express any desired therapeutic, including genome editors.
  • In vivo rodent data demonstrated a high degree of gene recombination after direct CNS injection using Evox’s proprietary exosome drug loading and release technology.
  • Development of exogenous loading platforms for functional targeted EV-mediated siRNA therapeutics delivery (PF09.09; poster): Levitin et al., report on progress loading of siRNA into/onto exosomes and demonstrate functional silencing activity of exosome-delivered siRNA.